A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA adverse event reporting system.

Published in: Expert opinion on drug safety (2024)

This pharmacovigilance study using AERS highlights potential higher risks of angioedema with losartan and irbesartan compared to other ARBs, warranting validation through prospective epidemiological studies to characterize individual ARB safety profiles.

Keyphrases

angiotensin converting enzyme
adverse drug
angiotensin ii
human health
drug induced
electronic health record
emergency department
risk assessment
binding protein